Drugs / Arterolane
Arterolane
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00362050 | Jun 2006 → Jan 2007 | Plasmodium falciparum malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02461186 | Jun 2015 → Jun 2017 | Plasmodium falciparum malaria | University of Oxford | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03452475 Comparator | Mar 2018 → Jun 2019 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | arterolane | “The present study assessed the efficacy and safety of 3 dose levels of arterolane (RBx 11160), a synthetic trioxolane, for treatment of acute uncomplicated falciparum malaria.” PMID 20687837 ↗ Sep 2010 |
| Known as | Arterolano | ChEMBL registry synonym — accepted as the source's own label CHEMBL404431 ↗ |
| Known as | OZ 277 | ChEMBL registry synonym — accepted as the source's own label CHEMBL404431 ↗ |
| Known as | RBx11160 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00362050 ↗ |
| Modality | Small molecule | “a synthetic trioxolane” PMID 20687837 ↗ Sep 2010 |
| Route | Oral | “administered as a single dose orally for 7 consecutive days” NCT00362050 ↗ |